METHOD: In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus genotype-1 co-infected patients receiving pegylated interferon-alpha-2b (peg-IFN2b) and ribavirin. We also tried to establish the underlying mechanisms that lead to poor sustained virologic responder rates observed with African-Americans against Caucasians and compared their results with those observed in a cohort of hepatitis C virus mono-infected patients. RESULTS: Among our studied population, a viral decline of more than 1.0 log at day 3 combined with viral load of less than 5.0 log IU/ml at day 28 predicted sustained virologic responders with negative predictive value 100% and positive predictive value 100%. African-Americans had significantly (P < 0.01) slower hepatitis C virus viral kinetics as compared to Caucasians. However, peg-IFN2b concentrations and pharmacokinetic parameters, peg-IFN2b(max) and peg-IFN2b half-life, were similar in both groups and did not predict sustained virologic responders. Nevertheless, the pharmacodynamic parameter EC(50), estimated from nonlinear fitting of the viral kinetics together with peg-IFN2b concentration data, showed that HIV/ hepatitis C virus co-infected African-Americans have lower sensitivity to interferon-alpha thus giving rise to slower viral decline. The combined pharmacokinetic/pharmacodynamic parameter IFN(max)/EC(90) was an excellent predictor of sustained virologic responders, thus showing the importance of maintaining peg-IFN2b levels above EC(90) to achieve successful treatment. CONCLUSION: Further studies are needed to evaluate whether these pharmacodynamic predictions are a result of differential host response to peg-IFN2b or other viral factors conferring relative resistance to peg-IFN2b.
METHOD: In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus genotype-1 co-infectedpatients receiving pegylated interferon-alpha-2b (peg-IFN2b) and ribavirin. We also tried to establish the underlying mechanisms that lead to poor sustained virologic responder rates observed with African-Americans against Caucasians and compared their results with those observed in a cohort of hepatitis C virus mono-infectedpatients. RESULTS: Among our studied population, a viral decline of more than 1.0 log at day 3 combined with viral load of less than 5.0 log IU/ml at day 28 predicted sustained virologic responders with negative predictive value 100% and positive predictive value 100%. African-Americans had significantly (P < 0.01) slower hepatitis C virus viral kinetics as compared to Caucasians. However, peg-IFN2b concentrations and pharmacokinetic parameters, peg-IFN2b(max) and peg-IFN2b half-life, were similar in both groups and did not predict sustained virologic responders. Nevertheless, the pharmacodynamic parameter EC(50), estimated from nonlinear fitting of the viral kinetics together with peg-IFN2b concentration data, showed that HIV/ hepatitis C virus co-infected African-Americans have lower sensitivity to interferon-alpha thus giving rise to slower viral decline. The combined pharmacokinetic/pharmacodynamic parameter IFN(max)/EC(90) was an excellent predictor of sustained virologic responders, thus showing the importance of maintaining peg-IFN2b levels above EC(90) to achieve successful treatment. CONCLUSION: Further studies are needed to evaluate whether these pharmacodynamic predictions are a result of differential host response to peg-IFN2b or other viral factors conferring relative resistance to peg-IFN2b.
Authors: Mamta K Jain; Daniel J Skiest; Jeff W Cloud; Charu L Jain; Dennis Burns; Ruth E Berggren Journal: Clin Infect Dis Date: 2003-04-02 Impact factor: 9.079
Authors: Montserrat Laguno; María Larrousse; Javier Murillas; José Luis Blanco; Agathe León; Ana Milinkovic; Montserrat Loncá; Esteban Martinez; José Maria Sánchez-Tapias; Elisa de Lazzari; Josep Maria Gatell; Josep Costa; Josep Mallolas Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: E S A Araújo; H Dahari; A U Neumann; N de Paula Cavalheiro; C E Melo; E S de Melo; T J Layden; S J Cotler; A A Barone Journal: J Viral Hepat Date: 2011-04 Impact factor: 3.728
Authors: Harel Dahari; Evaldo S Affonso de Araujo; Bart L Haagmans; Thomas J Layden; Scott J Cotler; Antonio A Barone; Avidan U Neumann Journal: J Hepatol Date: 2010-05-27 Impact factor: 25.083
Authors: Alison A Murphy; Eva Herrmann; Anu O Osinusi; Lynn Wu; William Sachau; Richard A Lempicki; Jun Yang; Tje L Chung; Tei L Chung; Brad J Wood; Bart L Haagmans; Shyam Kottilil; Michael A Polis Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil Journal: Hepatology Date: 2012-07-02 Impact factor: 17.425